Biohaven

Biohaven is a clinical stage biopharmaceutical company engaged in developing late-stage product candidates targeted at neurological and neuropsychiatric diseases, rare diseases and strategic therapeutic adjacencies. Since October 2022, Biohaven has operated independently following the acquisition agreement with Pfizer in May 2022. Pfizer holds about 3% ownership in the new spinoff, Biohaven Ltd.

As of October 2023, the company’s pipeline includes treatments for diseases including focal epilepsy, obsessive-compulsive disorder (OCD), spinocerebellar ataxia (SCA), and spinal muscular atrophy (SMA). Its lead drug candidate, troriluzole, is a third-generation prodrug for treating OCD and SCA, which is currently in Phase III clinical trials. 

In 2022, the global pharmaceutical company, Pfizer, acquired Biohaven for a consideration of USD 13 billion (approx.). The transaction agreements, including Pfizer’s commercialization of rimegepant and zavegepant (both used for the treatment of migraine) outside of the US became effective following the completion of this transaction. However, in October 2022, Biohaven began operating as a separate independent entity in connection with the merger agreement entered into with Pfizer Inc.

Funding and Financials

In October 2022 launched its public offering of common shares. At a price of USD 22.00 per share, the public offering was expected to raise approximately USD 225 million in gross proceeds.